Clinical Trials Logo

Multiple Myeloma, Refractory clinical trials

View clinical trials related to Multiple Myeloma, Refractory.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT05493618 Withdrawn - Clinical trials for Multiple Myeloma, Refractory

Pembrolizumab, Belantamab and Dexamethasone in Refractory Multiple Myeloma.

Start date: December 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a single arm, multi-institution (1) Hackensack Meridian Health at Hackensack, New Jersey (NJ) (2) Jersey Shore Medical Center, Neptune, NJ and (3) Georgetown/Lombardi Cancer Center) phase II study of the combination of pembrolizumab, belantamab, and dexamethasone in patients with triple class refractory multiple myeloma.